Attached files

file filename
EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc.ex99-1.htm
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 27, 2017
 
 
AZURRX BIOPHARMA, INC.
 
 
 
Delaware
001-37853
46-4993860
(State or Other Jurisdiction of
Incorporation or Organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
 
 
 
 
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New York

 
 
 
11226
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (646) 699-7855
(Name, address, including zip code, and telephone number, including area code, of agent for service of process)
 
NOT APPLICABLE
(Former Name or Former Address, if Changes Since Last Report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 
 
 
Item 8.01
Other Events
 
On September 27, 2017, the Company issued a press release announcing positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
 
Item 9.01  
Financial Statements and Exhibits
 
(d)    Exhibits.
 
Exhibit No.
 
Description
 
Press Release dated September 27, 2017
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
AzurRx BioPharma, Inc.
Date: September 27, 2017
By:
/s/ Johan M. Spoor
Name: Johan M. Spoor
Title: Chief Executive Officer
 
 
 
 
 
 
Exhibit Index
 
Exhibit No.
 
Description
 
Press Release dated September 27, 2017